James Hardie Counters Proxy Advisor, Urges Support for CEO Equity Grant
JHX sits 82% above its 52-week low of $16.46.
Summary
James Hardie filed additional proxy materials rebutting Ownership Matters' recommendation against the CEO equity grant, detailing compensation redesign and urging shareholders to vote 'for' all resolutions at the upcoming Annual Meeting.
Key Events · Corporate Governance and Compliance · JHX
-
Proxy Advisor Opposition Rebutted
Ownership Matters recommended voting against Proposal 4 (CEO Equity Grant); James Hardie's Board issued a detailed response urging shareholders to vote 'for' the proposal.
-
Compensation Redesign Defended
The Board highlights removal of the Scorecard LTI, introduction of a predominantly performance-based LTI for the CEO, and alignment of metrics with externally communicated guidance, responding to 2025 shareholder feedback.
-
FY26 Pay Outcomes Disclosed
FY24-26 relative TSR PRSUs did not vest; the Board applied negative discretion to FY26 STI, FY24-26 ROCE PRSUs, and the Scorecard LTI, with higher discretion for the CEO; FY26 Adjusted Net Income was below threshold, resulting in no payout.
-
Adjusted EBITDA Metric Defended
The Board argues adjusted EBITDA is a widely used U.S. market metric, and the averaging approach rewards sustained annual performance, not just cumulative outcomes, mitigating single-year volatility.
Analysis · JHX · Manufacturing
Ahead of the August 20/21 Annual Meeting, James Hardie is actively countering a proxy advisor's 'against' recommendation on its CEO equity grant proposal. The Board details the extensive shareholder engagement and compensation redesign undertaken after a disappointing 2025 vote, emphasizing the removal of the opaque Scorecard LTI, the shift to a predominantly performance-based structure, and the rigorous application of negative discretion in FY26. The rebuttal directly addresses criticisms of the adjusted EBITDA metric and the averaging approach, arguing they align with U.S. market practice and the company's public reporting. This is a critical governance moment — a 'no' vote could signal shareholder discontent with the new compensation framework, while a 'yes' validates the Board's responsiveness.
At the time of this filing, JHX was trading at $29.90 on NYSE in the Manufacturing sector, with a market capitalization of approximately $16.2B. The 52-week trading range was $16.46 to $29.83. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.